Computational drug design company Locus has successfully applied its novel technology in six external collaborations to date, which have demonstrated significant advantages in terms of novelty, cost and speed of development.
All of Locus’ internal development programs emanate from its computational technology and are focused on oral drug therapies, principally in cancer and inflammation.
“We are very pleased to be working with Amgen on this project and expanding our virtual fragment-based design approach,” said Dr Jeffrey Wiseman, vice president of technology & informatics at Locus. “Given our past molecular design experience across 10 classes of protein targets, we are confident that we will identify novel chemical classes of inhibitors for Amgen.”
Financial and other terms of the agreement were not disclosed.